Overview

Duration of Enzalutamide and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Status:
Not yet recruiting

Trial end date:
2030-07-01

Target enrollment:

Participant gender:

Summary

This is a multi-centre, investigator-initiated, two-arm, randomized trial to investigate the addition on enzalutamide to standard of care radiation and hormone therapy improve quality of life. Participants will either receive standard of care radiation and hormone (ADT) therapy (Arm 1) or standard of care radiation and hormone (ADT) therapy plus oral enzalutamide for 8 months (Arm 2). Participants will be routinely follow-up in clinic or remotely for up to 5 years.

Phase:

Phase 2

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

Astellas Pharma Inc